Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001002

Drug Information
NameNovobiocin
SynonymsStilbiocina; Spectrum2_000977; Novobiocine; Novo-R; KBio2_007538; C05080; ACon1_001693; 1aj6; ACon0_000808; KBio3_001615; Novobiocina [INN-Spanish]; DB01051; Albamycin; novobiocin; U 6391; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); AR-1A4403; KBioSS_002407; AI3-50148; SPBio_001013; (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; Streptonivicin; nchembio.2007.28-comp33; Spectrum3_000528; SMR000718617; Novobiocinum; HSDB 7443; Novobiocinum [INN-Latin]; 4309-70-0 (calcium salt); 303-81-1; Crystallinic acid; KBio1_000260; AC1L1SUS; CID9346; MEGxm0_000273; 1476-53-5; BRD-K85307935-236-02-0; [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; KBio2_006617; Cathomycin; KBio2_004970; C31H36N2O11; KBioSS_001481; Spectrum5_001274; Antibiotic PA-93; CHEMBL36506; Robiocina; LS-25404; Spectrum_001001; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); Novobiocin sodium salt; 4676-58-8; IDI1_000260; AC1Q6NLU; Novobiocina; cMAP_000043; Spectrum4_000457; NOV; MolPort-000-771-685; KBio2_004049; KBioGR_002402; DivK1c_000260; Cardelmycin; KBio3_002881; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one; 1476-53-5 (mono-hydrochloride salt); BSPBio_002115; Coumarin, 7-(4-(carbamoyloxy)tetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamido)-8-methyl-; KBio2_001481; PA 93; Spheromycin; Sirbiocina; EINECS 206-146-3; Albamix; NINDS_000260; Streptonivicin (*Sodium salt*); Novobiocine [INN-French]; UNII-17EC19951N; KST-1A4924; 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; Benzamide, N-(7-((3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-beta-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)-; KBio2_002402; KBioGR_000874; STOCK1N-34236; Inamycin; Novobiocin [INN:BAN]; MLS001032086; CHEBI:148697; Cathocin
Trade NameAlbamycin
CompanyPfizer Pharmaceuticals
IndicationBacterial infections
[ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104   ICD10: A00-A09, A15-A19, A20-A28, A30-A49, A65-A69, A70-A74, A75-A79]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntibacterial Agents
CAS NumberCAS 303-81-1
FormulaC31H36N2O11
PubChem Compound IDCID 9346.
PubChem Substance IDSID 7526.
SuperDrug ATC IDJ01XX95
TargetDNA gyraseInhibitor[2]
Ref 1How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. To Reference
Ref 2Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543